nodes	percent_of_prediction	percent_of_DWPC	metapath
Bisacodyl—GPR55—G alpha (i) signalling events—MTNR1A—type 2 diabetes mellitus	0.0107	0.0296	CbGpPWpGaD
Bisacodyl—GPR55—GPCRs, Other—EDNRA—type 2 diabetes mellitus	0.00912	0.0252	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—MTNR1A—type 2 diabetes mellitus	0.00853	0.0236	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—MTNR1A—type 2 diabetes mellitus	0.0065	0.0179	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—MC4R—type 2 diabetes mellitus	0.0062	0.0171	CbGpPWpGaD
Bisacodyl—GPR55—GPCRs, Other—CCR5—type 2 diabetes mellitus	0.00588	0.0162	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—MTNR1B—type 2 diabetes mellitus	0.00564	0.0156	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—GCGR—type 2 diabetes mellitus	0.00561	0.0155	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—GIPR—type 2 diabetes mellitus	0.00516	0.0143	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—ADRB3—type 2 diabetes mellitus	0.00507	0.014	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—AGTR2—type 2 diabetes mellitus	0.00472	0.0131	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—MC4R—type 2 diabetes mellitus	0.00472	0.013	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—GIP—type 2 diabetes mellitus	0.00454	0.0126	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—MTNR1B—type 2 diabetes mellitus	0.00448	0.0124	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CCKAR—type 2 diabetes mellitus	0.0043	0.0119	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—ADRA2A—type 2 diabetes mellitus	0.00418	0.0115	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—ADRB3—type 2 diabetes mellitus	0.00386	0.0107	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—AGTR2—type 2 diabetes mellitus	0.00376	0.0104	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CRHR1—type 2 diabetes mellitus	0.00373	0.0103	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—MTNR1A—type 2 diabetes mellitus	0.00367	0.0101	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—EDNRB—type 2 diabetes mellitus	0.0036	0.00994	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—HTR2C—type 2 diabetes mellitus	0.00349	0.00965	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—MTNR1B—type 2 diabetes mellitus	0.00341	0.00943	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Tolazamide—type 2 diabetes mellitus	0.0034	0.00538	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—EDNRA—type 2 diabetes mellitus	0.0034	0.00938	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Linagliptin—type 2 diabetes mellitus	0.00337	0.00533	CcSEcCtD
Bisacodyl—Angioedema—Rosiglitazone—type 2 diabetes mellitus	0.00335	0.00529	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—MTNR1A—type 2 diabetes mellitus	0.00333	0.00921	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—GLP1R—type 2 diabetes mellitus	0.00333	0.00919	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—ADRA2A—type 2 diabetes mellitus	0.00332	0.00918	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—GHRL—type 2 diabetes mellitus	0.00331	0.00914	CbGpPWpGaD
Bisacodyl—Diarrhoea—Miglitol—type 2 diabetes mellitus	0.0033	0.00521	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—GNB3—type 2 diabetes mellitus	0.00328	0.00907	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CCKAR—type 2 diabetes mellitus	0.00327	0.00904	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Acarbose—type 2 diabetes mellitus	0.00327	0.00517	CcSEcCtD
Bisacodyl—Immune system disorder—Pioglitazone—type 2 diabetes mellitus	0.00319	0.00504	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—GCGR—type 2 diabetes mellitus	0.00317	0.00876	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Repaglinide—type 2 diabetes mellitus	0.00316	0.005	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Nateglinide—type 2 diabetes mellitus	0.00315	0.00499	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Acarbose—type 2 diabetes mellitus	0.0031	0.0049	CcSEcCtD
Bisacodyl—Immune system disorder—Sitagliptin—type 2 diabetes mellitus	0.00309	0.00489	CcSEcCtD
Bisacodyl—Muscle spasms—Glipizide—type 2 diabetes mellitus	0.00308	0.00487	CcSEcCtD
Bisacodyl—Malnutrition—Pioglitazone—type 2 diabetes mellitus	0.00307	0.00486	CcSEcCtD
Bisacodyl—Abdominal discomfort—Gliclazide—type 2 diabetes mellitus	0.00305	0.00482	CcSEcCtD
Bisacodyl—Cramp muscle—Valsartan—type 2 diabetes mellitus	0.00304	0.00481	CcSEcCtD
Bisacodyl—Cramp muscle—Orlistat—type 2 diabetes mellitus	0.00301	0.00475	CcSEcCtD
Bisacodyl—Abdominal pain—Acarbose—type 2 diabetes mellitus	0.00299	0.00474	CcSEcCtD
Bisacodyl—Malnutrition—Glimepiride—type 2 diabetes mellitus	0.00299	0.00473	CcSEcCtD
Bisacodyl—Anaphylactic shock—Rosiglitazone—type 2 diabetes mellitus	0.00299	0.00472	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Nateglinide—type 2 diabetes mellitus	0.00299	0.00472	CcSEcCtD
Bisacodyl—Malnutrition—Sitagliptin—type 2 diabetes mellitus	0.00298	0.00471	CcSEcCtD
Bisacodyl—Muscle spasms—Pioglitazone—type 2 diabetes mellitus	0.00295	0.00467	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—IAPP—type 2 diabetes mellitus	0.00295	0.00814	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Rosiglitazone—type 2 diabetes mellitus	0.00293	0.00463	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—ADCY5—type 2 diabetes mellitus	0.00292	0.00808	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—GRK5—type 2 diabetes mellitus	0.00292	0.00806	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—GIPR—type 2 diabetes mellitus	0.00292	0.00806	CbGpPWpGaD
Bisacodyl—Abdominal pain—Nateglinide—type 2 diabetes mellitus	0.00289	0.00457	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GCGR—type 2 diabetes mellitus	0.00288	0.00795	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Linagliptin—type 2 diabetes mellitus	0.00287	0.00455	CcSEcCtD
Bisacodyl—Syncope—Glipizide—type 2 diabetes mellitus	0.00287	0.00454	CcSEcCtD
Bisacodyl—Muscle spasms—Sitagliptin—type 2 diabetes mellitus	0.00287	0.00453	CcSEcCtD
Bisacodyl—Nausea—Miglitol—type 2 diabetes mellitus	0.00286	0.00453	CcSEcCtD
Bisacodyl—Dehydration—Metformin—type 2 diabetes mellitus	0.00286	0.00453	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—AGTR2—type 2 diabetes mellitus	0.00286	0.0079	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Glipizide—type 2 diabetes mellitus	0.00282	0.00445	CcSEcCtD
Bisacodyl—Angioedema—Pioglitazone—type 2 diabetes mellitus	0.00281	0.00444	CcSEcCtD
Bisacodyl—Hypersensitivity—Acarbose—type 2 diabetes mellitus	0.00279	0.00441	CcSEcCtD
Bisacodyl—Cramp muscle—Metformin—type 2 diabetes mellitus	0.00277	0.00438	CcSEcCtD
Bisacodyl—Abdominal discomfort—Orlistat—type 2 diabetes mellitus	0.00277	0.00437	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—CCR5—type 2 diabetes mellitus	0.00275	0.00761	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—EDNRB—type 2 diabetes mellitus	0.00274	0.00757	CbGpPWpGaD
Bisacodyl—Angioedema—Glimepiride—type 2 diabetes mellitus	0.00273	0.00432	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Repaglinide—type 2 diabetes mellitus	0.00273	0.00432	CcSEcCtD
Bisacodyl—Angioedema—Sitagliptin—type 2 diabetes mellitus	0.00272	0.00431	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ARAP1—type 2 diabetes mellitus	0.00272	0.00753	CbGpPWpGaD
Bisacodyl—Headache—Tolbutamide—type 2 diabetes mellitus	0.00272	0.00429	CcSEcCtD
Bisacodyl—Diarrhoea—Chlorpropamide—type 2 diabetes mellitus	0.0027	0.00427	CcSEcCtD
Bisacodyl—Hypersensitivity—Nateglinide—type 2 diabetes mellitus	0.00269	0.00426	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—C3—type 2 diabetes mellitus	0.00269	0.00743	CbGpPWpGaD
Bisacodyl—Diarrhoea—Linagliptin—type 2 diabetes mellitus	0.00267	0.00422	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—MC4R—type 2 diabetes mellitus	0.00267	0.00737	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—HTR2C—type 2 diabetes mellitus	0.00266	0.00735	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—GRK5—type 2 diabetes mellitus	0.00265	0.00732	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—GIPR—type 2 diabetes mellitus	0.00265	0.00732	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Glimepiride—type 2 diabetes mellitus	0.00263	0.00416	CcSEcCtD
Bisacodyl—Cramp muscle—Irbesartan—type 2 diabetes mellitus	0.00262	0.00413	CcSEcCtD
Bisacodyl—Dizziness—Tolazamide—type 2 diabetes mellitus	0.00261	0.00412	CcSEcCtD
Bisacodyl—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.00261	0.00412	CcSEcCtD
Bisacodyl—Muscle spasms—Bromocriptine—type 2 diabetes mellitus	0.00259	0.0041	CcSEcCtD
Bisacodyl—Diarrhoea—Acarbose—type 2 diabetes mellitus	0.00259	0.0041	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—EDNRA—type 2 diabetes mellitus	0.00259	0.00715	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Repaglinide—type 2 diabetes mellitus	0.00259	0.00409	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Rosiglitazone—type 2 diabetes mellitus	0.00258	0.00408	CcSEcCtD
Bisacodyl—Nausea—Tolbutamide—type 2 diabetes mellitus	0.00257	0.00407	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—AVP—type 2 diabetes mellitus	0.00257	0.00711	CbGpPWpGaD
Bisacodyl—Shock—Glipizide—type 2 diabetes mellitus	0.00257	0.00407	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—GIP—type 2 diabetes mellitus	0.00257	0.00709	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—AGT—type 2 diabetes mellitus	0.00256	0.00706	CbGpPWpGaD
Bisacodyl—Abdominal discomfort—Metformin—type 2 diabetes mellitus	0.00255	0.00403	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—ADRA2A—type 2 diabetes mellitus	0.00253	0.00699	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—GHRL—type 2 diabetes mellitus	0.00252	0.00696	CbGpPWpGaD
Bisacodyl—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.00251	0.00396	CcSEcCtD
Bisacodyl—Anaphylactic shock—Pioglitazone—type 2 diabetes mellitus	0.00251	0.00396	CcSEcCtD
Bisacodyl—Abdominal pain—Repaglinide—type 2 diabetes mellitus	0.0025	0.00395	CcSEcCtD
Bisacodyl—Diarrhoea—Nateglinide—type 2 diabetes mellitus	0.0025	0.00395	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—VPS26A—type 2 diabetes mellitus	0.00249	0.00688	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CALCA—type 2 diabetes mellitus	0.00249	0.00688	CbGpPWpGaD
Bisacodyl—Headache—Tolazamide—type 2 diabetes mellitus	0.00247	0.00391	CcSEcCtD
Bisacodyl—Headache—Chlorpropamide—type 2 diabetes mellitus	0.00247	0.00391	CcSEcCtD
Bisacodyl—Malnutrition—Glyburide—type 2 diabetes mellitus	0.00247	0.0039	CcSEcCtD
Bisacodyl—Cramp muscle—Losartan—type 2 diabetes mellitus	0.00246	0.00389	CcSEcCtD
Bisacodyl—Nervous system disorder—Pioglitazone—type 2 diabetes mellitus	0.00246	0.00389	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—EDN1—type 2 diabetes mellitus	0.00245	0.00676	CbGpPWpGaD
Bisacodyl—Headache—Linagliptin—type 2 diabetes mellitus	0.00244	0.00387	CcSEcCtD
Bisacodyl—Anaphylactic shock—Glimepiride—type 2 diabetes mellitus	0.00244	0.00386	CcSEcCtD
Bisacodyl—Anaphylactic shock—Sitagliptin—type 2 diabetes mellitus	0.00243	0.00385	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—MC4R—type 2 diabetes mellitus	0.00242	0.00669	CbGpPWpGaD
Bisacodyl—Syncope—Bromocriptine—type 2 diabetes mellitus	0.00242	0.00383	CcSEcCtD
Bisacodyl—Dizziness—Nateglinide—type 2 diabetes mellitus	0.00242	0.00382	CcSEcCtD
Bisacodyl—Vomiting—Acarbose—type 2 diabetes mellitus	0.00241	0.00381	CcSEcCtD
Bisacodyl—Shock—Glimepiride—type 2 diabetes mellitus	0.0024	0.0038	CcSEcCtD
Bisacodyl—Nervous system disorder—Sitagliptin—type 2 diabetes mellitus	0.00239	0.00377	CcSEcCtD
Bisacodyl—Loss of consciousness—Bromocriptine—type 2 diabetes mellitus	0.00237	0.00375	CcSEcCtD
Bisacodyl—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.00234	0.0037	CcSEcCtD
Bisacodyl—Nausea—Tolazamide—type 2 diabetes mellitus	0.00234	0.0037	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GIP—type 2 diabetes mellitus	0.00233	0.00644	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.00233	0.00368	CcSEcCtD
Bisacodyl—Vomiting—Nateglinide—type 2 diabetes mellitus	0.00232	0.00367	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—GCG—type 2 diabetes mellitus	0.00231	0.00637	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Glipizide—type 2 diabetes mellitus	0.00226	0.00357	CcSEcCtD
Bisacodyl—Angioedema—Glyburide—type 2 diabetes mellitus	0.00225	0.00356	CcSEcCtD
Bisacodyl—Nausea—Acarbose—type 2 diabetes mellitus	0.00225	0.00356	CcSEcCtD
Bisacodyl—Malnutrition—Gliclazide—type 2 diabetes mellitus	0.00221	0.0035	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CCR5—type 2 diabetes mellitus	0.00219	0.00605	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—ADRB3—type 2 diabetes mellitus	0.00218	0.00603	CbGpPWpGaD
Bisacodyl—Nausea—Nateglinide—type 2 diabetes mellitus	0.00217	0.00343	CcSEcCtD
Bisacodyl—Shock—Bromocriptine—type 2 diabetes mellitus	0.00217	0.00343	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	0.00216	0.00342	CcSEcCtD
Bisacodyl—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.00216	0.00342	CcSEcCtD
Bisacodyl—Nervous system disorder—Bromocriptine—type 2 diabetes mellitus	0.00216	0.00341	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Glipizide—type 2 diabetes mellitus	0.00214	0.00338	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—C3—type 2 diabetes mellitus	0.00214	0.00591	CbGpPWpGaD
Bisacodyl—Immune system disorder—Valsartan—type 2 diabetes mellitus	0.00211	0.00334	CcSEcCtD
Bisacodyl—Cramp muscle—Ramipril—type 2 diabetes mellitus	0.00211	0.00334	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CRHR1—type 2 diabetes mellitus	0.00211	0.00583	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.00211	0.00333	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.0021	0.00332	CcSEcCtD
Bisacodyl—Immune system disorder—Orlistat—type 2 diabetes mellitus	0.00209	0.0033	CcSEcCtD
Bisacodyl—Abdominal pain—Glipizide—type 2 diabetes mellitus	0.00207	0.00327	CcSEcCtD
Bisacodyl—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.00204	0.00323	CcSEcCtD
Bisacodyl—Malnutrition—Valsartan—type 2 diabetes mellitus	0.00203	0.00322	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—AGT—type 2 diabetes mellitus	0.00203	0.00561	CbGpPWpGaD
Bisacodyl—Angioedema—Gliclazide—type 2 diabetes mellitus	0.00202	0.0032	CcSEcCtD
Bisacodyl—Malnutrition—Orlistat—type 2 diabetes mellitus	0.00201	0.00318	CcSEcCtD
Bisacodyl—Vomiting—Repaglinide—type 2 diabetes mellitus	0.00201	0.00318	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Glimepiride—type 2 diabetes mellitus	0.002	0.00316	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Sitagliptin—type 2 diabetes mellitus	0.00199	0.00315	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—GNB3—type 2 diabetes mellitus	0.00199	0.00549	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—ADRB3—type 2 diabetes mellitus	0.00198	0.00548	CbGpPWpGaD
Bisacodyl—Headache—Repaglinide—type 2 diabetes mellitus	0.00198	0.00313	CcSEcCtD
Bisacodyl—Shock—Glyburide—type 2 diabetes mellitus	0.00198	0.00313	CcSEcCtD
Bisacodyl—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.00198	0.00312	CcSEcCtD
Bisacodyl—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.00197	0.00312	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—MTNR1A—type 2 diabetes mellitus	0.00197	0.00544	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—AVP—type 2 diabetes mellitus	0.00196	0.00542	CbGpPWpGaD
Bisacodyl—Muscle spasms—Valsartan—type 2 diabetes mellitus	0.00196	0.00309	CcSEcCtD
Bisacodyl—Loss of consciousness—Gliclazide—type 2 diabetes mellitus	0.00195	0.00308	CcSEcCtD
Bisacodyl—Abdominal discomfort—Ramipril—type 2 diabetes mellitus	0.00194	0.00307	CcSEcCtD
Bisacodyl—Muscle spasms—Orlistat—type 2 diabetes mellitus	0.00193	0.00306	CcSEcCtD
Bisacodyl—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.00193	0.00305	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—MTNR1B—type 2 diabetes mellitus	0.00193	0.00533	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.00193	0.00305	CcSEcCtD
Bisacodyl—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.00192	0.00304	CcSEcCtD
Bisacodyl—Immune system disorder—Metformin—type 2 diabetes mellitus	0.00192	0.00304	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CRHR1—type 2 diabetes mellitus	0.00191	0.00529	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.0019	0.00301	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—GLP1R—type 2 diabetes mellitus	0.00188	0.00519	CbGpPWpGaD
Bisacodyl—Nausea—Repaglinide—type 2 diabetes mellitus	0.00188	0.00297	CcSEcCtD
Bisacodyl—Headache—Rosiglitazone—type 2 diabetes mellitus	0.00187	0.00296	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—EDN1—type 2 diabetes mellitus	0.00186	0.00515	CbGpPWpGaD
Bisacodyl—Angioedema—Valsartan—type 2 diabetes mellitus	0.00186	0.00294	CcSEcCtD
Bisacodyl—Malnutrition—Metformin—type 2 diabetes mellitus	0.00185	0.00293	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CCKAR—type 2 diabetes mellitus	0.00185	0.00511	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.00185	0.00292	CcSEcCtD
Bisacodyl—Angioedema—Orlistat—type 2 diabetes mellitus	0.00184	0.00291	CcSEcCtD
Bisacodyl—Syncope—Valsartan—type 2 diabetes mellitus	0.00182	0.00289	CcSEcCtD
Bisacodyl—Immune system disorder—Irbesartan—type 2 diabetes mellitus	0.00181	0.00287	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.0018	0.00285	CcSEcCtD
Bisacodyl—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.0018	0.00284	CcSEcCtD
Bisacodyl—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.00179	0.00283	CcSEcCtD
Bisacodyl—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.00179	0.00283	CcSEcCtD
Bisacodyl—Loss of consciousness—Valsartan—type 2 diabetes mellitus	0.00179	0.00283	CcSEcCtD
Bisacodyl—Muscle spasms—Metformin—type 2 diabetes mellitus	0.00178	0.00282	CcSEcCtD
Bisacodyl—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00177	0.00281	CcSEcCtD
Bisacodyl—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.00177	0.0028	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—MTNR1B—type 2 diabetes mellitus	0.00175	0.00484	CbGpPWpGaD
Bisacodyl—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.00175	0.00277	CcSEcCtD
Bisacodyl—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.00174	0.00275	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.00174	0.00275	CcSEcCtD
Bisacodyl—Dizziness—Glipizide—type 2 diabetes mellitus	0.00173	0.00274	CcSEcCtD
Bisacodyl—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.00171	0.00271	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GLP1R—type 2 diabetes mellitus	0.00171	0.00472	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GCGR—type 2 diabetes mellitus	0.0017	0.0047	CbGpPWpGaD
Bisacodyl—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.00168	0.00266	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CCKAR—type 2 diabetes mellitus	0.00168	0.00464	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CCL2—type 2 diabetes mellitus	0.00167	0.00462	CbGpPWpGaD
Bisacodyl—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.00167	0.00264	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—CCR5—type 2 diabetes mellitus	0.00167	0.0046	CbGpPWpGaD
Bisacodyl—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.00166	0.00263	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—IAPP—type 2 diabetes mellitus	0.00166	0.0046	CbGpPWpGaD
Bisacodyl—Vomiting—Glipizide—type 2 diabetes mellitus	0.00166	0.00263	CcSEcCtD
Bisacodyl—Syncope—Metformin—type 2 diabetes mellitus	0.00166	0.00263	CcSEcCtD
Bisacodyl—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.00166	0.00263	CcSEcCtD
Bisacodyl—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.00166	0.00262	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.00165	0.0026	CcSEcCtD
Bisacodyl—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.00164	0.00259	CcSEcCtD
Bisacodyl—Headache—Glipizide—type 2 diabetes mellitus	0.00164	0.00259	CcSEcCtD
Bisacodyl—Shock—Valsartan—type 2 diabetes mellitus	0.00163	0.00258	CcSEcCtD
Bisacodyl—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.00163	0.00258	CcSEcCtD
Bisacodyl—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.00163	0.00258	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—C3—type 2 diabetes mellitus	0.00163	0.0045	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—TRPC6—type 2 diabetes mellitus	0.00163	0.00449	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—AGTR2—type 2 diabetes mellitus	0.00162	0.00447	CbGpPWpGaD
Bisacodyl—Dizziness—Glimepiride—type 2 diabetes mellitus	0.00161	0.00255	CcSEcCtD
Bisacodyl—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.00161	0.00254	CcSEcCtD
Bisacodyl—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.00161	0.00254	CcSEcCtD
Bisacodyl—Angioedema—Irbesartan—type 2 diabetes mellitus	0.0016	0.00253	CcSEcCtD
Bisacodyl—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.00159	0.00252	CcSEcCtD
Bisacodyl—Muscle spasms—Losartan—type 2 diabetes mellitus	0.00158	0.0025	CcSEcCtD
Bisacodyl—Carbinoxamine—CYP2E1—type 2 diabetes mellitus	0.00158	0.28	CrCbGaD
Bisacodyl—Headache—Pioglitazone—type 2 diabetes mellitus	0.00157	0.00248	CcSEcCtD
Bisacodyl—Syncope—Irbesartan—type 2 diabetes mellitus	0.00157	0.00248	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—GIPR—type 2 diabetes mellitus	0.00156	0.00432	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GRK5—type 2 diabetes mellitus	0.00156	0.00432	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.00156	0.00247	CcSEcCtD
Bisacodyl—Nausea—Glipizide—type 2 diabetes mellitus	0.00155	0.00246	CcSEcCtD
Bisacodyl—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00155	0.00245	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—EDNRB—type 2 diabetes mellitus	0.00155	0.00428	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—AGT—type 2 diabetes mellitus	0.00155	0.00428	CbGpPWpGaD
Bisacodyl—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00155	0.00245	CcSEcCtD
Bisacodyl—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.00154	0.00243	CcSEcCtD
Bisacodyl—Headache—Glimepiride—type 2 diabetes mellitus	0.00153	0.00242	CcSEcCtD
Bisacodyl—Headache—Sitagliptin—type 2 diabetes mellitus	0.00152	0.00241	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—IAPP—type 2 diabetes mellitus	0.00151	0.00418	CbGpPWpGaD
Bisacodyl—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.00151	0.00238	CcSEcCtD
Bisacodyl—Angioedema—Losartan—type 2 diabetes mellitus	0.0015	0.00238	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—HTR2C—type 2 diabetes mellitus	0.0015	0.00415	CbGpPWpGaD
Bisacodyl—Shock—Metformin—type 2 diabetes mellitus	0.00149	0.00235	CcSEcCtD
Bisacodyl—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.00148	0.00235	CcSEcCtD
Bisacodyl—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.00148	0.00235	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.00148	0.00234	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—TRPC6—type 2 diabetes mellitus	0.00148	0.00408	CbGpPWpGaD
Bisacodyl—Syncope—Losartan—type 2 diabetes mellitus	0.00148	0.00233	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—AGTR2—type 2 diabetes mellitus	0.00147	0.00406	CbGpPWpGaD
Bisacodyl—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.00146	0.00232	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—EDNRA—type 2 diabetes mellitus	0.00146	0.00404	CbGpPWpGaD
Bisacodyl—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.00146	0.0023	CcSEcCtD
Bisacodyl—Nausea—Glimepiride—type 2 diabetes mellitus	0.00145	0.00229	CcSEcCtD
Bisacodyl—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.00145	0.00229	CcSEcCtD
Bisacodyl—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00145	0.00229	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.00143	0.00227	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—MC4R—type 2 diabetes mellitus	0.00143	0.00395	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—ADRA2A—type 2 diabetes mellitus	0.00143	0.00395	CbGpPWpGaD
Bisacodyl—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.00143	0.00226	CcSEcCtD
Bisacodyl—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.00143	0.00226	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	0.00142	0.00394	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.00142	0.00224	CcSEcCtD
Bisacodyl—Malnutrition—Ramipril—type 2 diabetes mellitus	0.00141	0.00223	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	0.00141	0.00389	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	0.00141	0.00388	CbGpPWpGaD
Bisacodyl—Shock—Irbesartan—type 2 diabetes mellitus	0.0014	0.00222	CcSEcCtD
Bisacodyl—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.0014	0.00221	CcSEcCtD
Bisacodyl—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.0014	0.00221	CcSEcCtD
Bisacodyl—Headache—Bromocriptine—type 2 diabetes mellitus	0.00138	0.00218	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—GIP—type 2 diabetes mellitus	0.00138	0.00381	CbGpPWpGaD
Bisacodyl—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.00138	0.00218	CcSEcCtD
Bisacodyl—Brompheniramine—CYP2E1—type 2 diabetes mellitus	0.00136	0.242	CrCbGaD
Bisacodyl—GPR55—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	0.00136	0.00377	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.00136	0.00215	CcSEcCtD
Bisacodyl—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.00136	0.00215	CcSEcCtD
Bisacodyl—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.00134	0.00212	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.00134	0.00212	CcSEcCtD
Bisacodyl—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.00133	0.00211	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	0.00133	0.00367	CbGpPWpGaD
Bisacodyl—Shock—Losartan—type 2 diabetes mellitus	0.00132	0.00209	CcSEcCtD
Bisacodyl—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.00132	0.00208	CcSEcCtD
Bisacodyl—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.00131	0.00208	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—LEPR—type 2 diabetes mellitus	0.00131	0.00362	CbGpPWpGaD
Bisacodyl—Nausea—Bromocriptine—type 2 diabetes mellitus	0.00131	0.00207	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.00131	0.00206	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—GCG—type 2 diabetes mellitus	0.0013	0.0036	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	0.0013	0.00359	CbGpPWpGaD
Bisacodyl—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.0013	0.00205	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GHRL—type 2 diabetes mellitus	0.00129	0.00357	CbGpPWpGaD
Bisacodyl—Angioedema—Ramipril—type 2 diabetes mellitus	0.00129	0.00204	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	0.00128	0.00354	CbGpPWpGaD
Bisacodyl—Vomiting—Glyburide—type 2 diabetes mellitus	0.00128	0.00202	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CALCA—type 2 diabetes mellitus	0.00128	0.00353	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CCL2—type 2 diabetes mellitus	0.00127	0.00352	CbGpPWpGaD
Bisacodyl—Syncope—Ramipril—type 2 diabetes mellitus	0.00127	0.002	CcSEcCtD
Bisacodyl—Headache—Glyburide—type 2 diabetes mellitus	0.00126	0.00199	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	0.00125	0.00346	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.00124	0.00196	CcSEcCtD
Bisacodyl—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.00124	0.00196	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.00124	0.00196	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.00123	0.00195	CcSEcCtD
Bisacodyl—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.00122	0.00193	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—TLE4—type 2 diabetes mellitus	0.00122	0.00336	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.00121	0.00191	CcSEcCtD
Bisacodyl—Nausea—Glyburide—type 2 diabetes mellitus	0.0012	0.00189	CcSEcCtD
Bisacodyl—Abdominal pain—Metformin—type 2 diabetes mellitus	0.0012	0.00189	CcSEcCtD
Bisacodyl—Dizziness—Gliclazide—type 2 diabetes mellitus	0.0012	0.00189	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GCG—type 2 diabetes mellitus	0.00118	0.00327	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—ADRB3—type 2 diabetes mellitus	0.00117	0.00324	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.00117	0.00185	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	0.00116	0.00322	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.00115	0.00182	CcSEcCtD
Bisacodyl—Vomiting—Gliclazide—type 2 diabetes mellitus	0.00115	0.00182	CcSEcCtD
Bisacodyl—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.00114	0.0018	CcSEcCtD
Bisacodyl—Shock—Ramipril—type 2 diabetes mellitus	0.00113	0.00179	CcSEcCtD
Bisacodyl—Headache—Gliclazide—type 2 diabetes mellitus	0.00113	0.00179	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CRHR1—type 2 diabetes mellitus	0.00113	0.00313	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.00113	0.00179	CcSEcCtD
Bisacodyl—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.00113	0.00178	CcSEcCtD
Bisacodyl—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.00112	0.00178	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	0.00112	0.0031	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—AVP—type 2 diabetes mellitus	0.00111	0.00306	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.0011	0.00174	CcSEcCtD
Bisacodyl—Dizziness—Valsartan—type 2 diabetes mellitus	0.0011	0.00174	CcSEcCtD
Bisacodyl—Dizziness—Orlistat—type 2 diabetes mellitus	0.00109	0.00172	CcSEcCtD
Bisacodyl—Nausea—Gliclazide—type 2 diabetes mellitus	0.00107	0.0017	CcSEcCtD
Bisacodyl—Abdominal pain—Losartan—type 2 diabetes mellitus	0.00106	0.00168	CcSEcCtD
Bisacodyl—Vomiting—Valsartan—type 2 diabetes mellitus	0.00106	0.00167	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	0.00105	0.00291	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.00105	0.00166	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	0.00104	0.00288	CbGpPWpGaD
Bisacodyl—Vomiting—Orlistat—type 2 diabetes mellitus	0.00104	0.00165	CcSEcCtD
Bisacodyl—Headache—Valsartan—type 2 diabetes mellitus	0.00104	0.00165	CcSEcCtD
Bisacodyl—Diarrhoea—Metformin—type 2 diabetes mellitus	0.00103	0.00164	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—SPRY2—type 2 diabetes mellitus	0.00103	0.00286	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	0.00103	0.00286	CbGpPWpGaD
Bisacodyl—Headache—Orlistat—type 2 diabetes mellitus	0.00103	0.00163	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GNB3—type 2 diabetes mellitus	0.00102	0.00282	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—RBP4—type 2 diabetes mellitus	0.00101	0.00279	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GLP1R—type 2 diabetes mellitus	0.00101	0.00279	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—AVP—type 2 diabetes mellitus	0.00101	0.00278	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—MMP3—type 2 diabetes mellitus	0.00101	0.00278	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	0.001	0.00277	CbGpPWpGaD
Bisacodyl—Dizziness—Metformin—type 2 diabetes mellitus	0.001	0.00158	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000994	0.00157	CcSEcCtD
Bisacodyl—Carbinoxamine—CYP3A4—type 2 diabetes mellitus	0.000992	0.176	CrCbGaD
Bisacodyl—GPR55—Signaling Pathways—CCKAR—type 2 diabetes mellitus	0.000992	0.00274	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.00099	0.00156	CcSEcCtD
Bisacodyl—Nausea—Valsartan—type 2 diabetes mellitus	0.000987	0.00156	CcSEcCtD
Bisacodyl—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000977	0.00154	CcSEcCtD
Bisacodyl—Nausea—Orlistat—type 2 diabetes mellitus	0.000975	0.00154	CcSEcCtD
Bisacodyl—Vomiting—Metformin—type 2 diabetes mellitus	0.000962	0.00152	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—EDN1—type 2 diabetes mellitus	0.000957	0.00264	CbGpPWpGaD
Bisacodyl—Headache—Metformin—type 2 diabetes mellitus	0.000947	0.0015	CcSEcCtD
Bisacodyl—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000944	0.00149	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	0.000942	0.0026	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000942	0.00149	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—C3—type 2 diabetes mellitus	0.00092	0.00254	CbGpPWpGaD
Bisacodyl—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000919	0.00145	CcSEcCtD
Bisacodyl—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.00091	0.00144	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	0.000909	0.00251	CbGpPWpGaD
Bisacodyl—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000907	0.00143	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	0.000899	0.00248	CbGpPWpGaD
Bisacodyl—Nausea—Metformin—type 2 diabetes mellitus	0.000898	0.00142	CcSEcCtD
Bisacodyl—Headache—Irbesartan—type 2 diabetes mellitus	0.000894	0.00141	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—IAPP—type 2 diabetes mellitus	0.000893	0.00247	CbGpPWpGaD
Bisacodyl—Dizziness—Losartan—type 2 diabetes mellitus	0.000888	0.0014	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—INSR—type 2 diabetes mellitus	0.000888	0.00245	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—AGT—type 2 diabetes mellitus	0.000875	0.00242	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TRPC6—type 2 diabetes mellitus	0.000872	0.00241	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	0.000871	0.00241	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—AGTR2—type 2 diabetes mellitus	0.000867	0.0024	CbGpPWpGaD
Bisacodyl—Brompheniramine—CYP3A4—type 2 diabetes mellitus	0.000859	0.153	CrCbGaD
Bisacodyl—GPR55—Signaling by GPCR—CCR5—type 2 diabetes mellitus	0.000855	0.00236	CbGpPWpGaD
Bisacodyl—Vomiting—Losartan—type 2 diabetes mellitus	0.000854	0.00135	CcSEcCtD
Bisacodyl—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000849	0.00134	CcSEcCtD
Bisacodyl—Nausea—Irbesartan—type 2 diabetes mellitus	0.000848	0.00134	CcSEcCtD
Bisacodyl—Chlorphenamine—CYP3A4—type 2 diabetes mellitus	0.000844	0.15	CrCbGaD
Bisacodyl—Headache—Losartan—type 2 diabetes mellitus	0.000841	0.00133	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—C3—type 2 diabetes mellitus	0.000836	0.00231	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—EDNRB—type 2 diabetes mellitus	0.00083	0.00229	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	0.000808	0.00223	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PSMD6—type 2 diabetes mellitus	0.000806	0.00223	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HTR2C—type 2 diabetes mellitus	0.000806	0.00223	CbGpPWpGaD
Bisacodyl—Nausea—Losartan—type 2 diabetes mellitus	0.000798	0.00126	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—AGT—type 2 diabetes mellitus	0.000794	0.00219	CbGpPWpGaD
Bisacodyl—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000788	0.00125	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—EDNRA—type 2 diabetes mellitus	0.000784	0.00217	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—CALM1—type 2 diabetes mellitus	0.000781	0.00216	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CYBA—type 2 diabetes mellitus	0.000781	0.00216	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	0.000767	0.00212	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GHRL—type 2 diabetes mellitus	0.000764	0.00211	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PLAT—type 2 diabetes mellitus	0.000764	0.00211	CbGpPWpGaD
Bisacodyl—Dizziness—Ramipril—type 2 diabetes mellitus	0.000762	0.0012	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CALCA—type 2 diabetes mellitus	0.000755	0.00209	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	0.000734	0.00203	CbGpPWpGaD
Bisacodyl—Vomiting—Ramipril—type 2 diabetes mellitus	0.000732	0.00116	CcSEcCtD
Bisacodyl—Headache—Ramipril—type 2 diabetes mellitus	0.000722	0.00114	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	0.000711	0.00196	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	0.000708	0.00195	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PTPN1—type 2 diabetes mellitus	0.000699	0.00193	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GCG—type 2 diabetes mellitus	0.000699	0.00193	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	0.000688	0.0019	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	0.000685	0.00189	CbGpPWpGaD
Bisacodyl—Nausea—Ramipril—type 2 diabetes mellitus	0.000684	0.00108	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CCL2—type 2 diabetes mellitus	0.000654	0.00181	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—AKT2—type 2 diabetes mellitus	0.000643	0.00178	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	0.000642	0.00177	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	0.000608	0.00168	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GNB3—type 2 diabetes mellitus	0.000602	0.00166	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—AVP—type 2 diabetes mellitus	0.000594	0.00164	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MMP3—type 2 diabetes mellitus	0.000594	0.00164	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IGF2—type 2 diabetes mellitus	0.000592	0.00163	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	0.000589	0.00163	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	0.000583	0.00161	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—APOB—type 2 diabetes mellitus	0.000574	0.00159	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IGF1R—type 2 diabetes mellitus	0.000572	0.00158	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—EDN1—type 2 diabetes mellitus	0.000565	0.00156	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—LPL—type 2 diabetes mellitus	0.000548	0.00152	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—ADCY5—type 2 diabetes mellitus	0.000537	0.00148	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	0.000515	0.00142	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CCR5—type 2 diabetes mellitus	0.000505	0.0014	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—C3—type 2 diabetes mellitus	0.000494	0.00136	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HIF1A—type 2 diabetes mellitus	0.000471	0.0013	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IRS2—type 2 diabetes mellitus	0.00047	0.0013	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—AGT—type 2 diabetes mellitus	0.000469	0.0013	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CALM1—type 2 diabetes mellitus	0.000461	0.00127	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—LEP—type 2 diabetes mellitus	0.00046	0.00127	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—APOE—type 2 diabetes mellitus	0.00046	0.00127	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—APOA1—type 2 diabetes mellitus	0.000454	0.00126	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PRKCB—type 2 diabetes mellitus	0.000433	0.0012	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IRS1—type 2 diabetes mellitus	0.00041	0.00113	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—INS—type 2 diabetes mellitus	0.000393	0.00108	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CCL2—type 2 diabetes mellitus	0.000386	0.00107	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IGF1—type 2 diabetes mellitus	0.00038	0.00105	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—AKT2—type 2 diabetes mellitus	0.00038	0.00105	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—EGFR—type 2 diabetes mellitus	0.000378	0.00104	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	0.000361	0.000997	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	0.000344	0.000951	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NOS3—type 2 diabetes mellitus	0.000344	0.000951	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—RELA—type 2 diabetes mellitus	0.000324	0.000896	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	0.000295	0.000815	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CASP3—type 2 diabetes mellitus	0.000292	0.000808	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—IL6—type 2 diabetes mellitus	0.00029	0.000803	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MMP9—type 2 diabetes mellitus	0.000276	0.000763	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NFKB1—type 2 diabetes mellitus	0.000273	0.000755	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—AKT1—type 2 diabetes mellitus	0.000268	0.00074	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SRC—type 2 diabetes mellitus	0.000255	0.000704	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—VEGFA—type 2 diabetes mellitus	0.000248	0.000685	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TGFB1—type 2 diabetes mellitus	0.000228	0.000629	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—EGFR—type 2 diabetes mellitus	0.000223	0.000617	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IL6—type 2 diabetes mellitus	0.000172	0.000474	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—AKT1—type 2 diabetes mellitus	0.000158	0.000437	CbGpPWpGaD
